Skip to main content
    C

    Cadrenal Therapeutics, Inc. Common Stock (CVKD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.40
    -0.11 (-7.28%)

    Market Cap: $5.39M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Cadrenal Therapeutics, Inc. Common Stock (CVKD) Earnings: Report Dates and Results

    Updated Aug 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Cadrenal Therapeutics, Inc. Common Stock (CVKD) is expected to report earnings on Mar 29, 2027. In the quarter ended Jun 30, 2026, Cadrenal Therapeutics, Inc. Common Stock reported EPS of -$1.14, above the -$1.16 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(4/10)
    Avg Surprise
    -1.84%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.88
    RangeN/A
    5 analysts
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts

    Next Report

    CVKD has an expected report date of Mar 29, 2027.

    Earnings History

    Of the 10 quarters below that had an estimate, CVKD beat 4 and missed 6. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 37.50% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Jun 30, 2026-$1.14-$1.16N/A+1.72%BeatN/A10 up, 0 downAug 13, 2026
    Mar 31, 2026-$1.04-$1.57-$1.86 - -$1.29+33.76%BeatN/A20 up, 0 downMay 7, 2026
    Dec 31, 2025-$1.41-$1.21-$1.21 - -$1.21-16.53%MissN/A10 up, 0 downMar 31, 2026
    Sep 30, 2025-$1.31-$1.55-$1.55 - -$1.55+15.48%BeatN/A10 up, 0 downNov 10, 2025
    Jun 30, 2025-$1.87-$1.77-$2.07 - -$1.48-5.65%MissN/A20 up, 0 downAug 11, 2025
    Mar 31, 2025-$2.09-$1.64N/A-27.44%MissN/A10 up, 0 downMay 8, 2025
    Dec 31, 2024-$2.55-$0.15N/AN/AN/AN/A20 up, 1 downMar 13, 2025
    Sep 30, 2024-$2.18-$1.80-$2.40 - -$1.20-21.11%MissN/A30 up, 0 downNov 7, 2024
    Jun 30, 2024-$2.25-$1.80-$1.80 - -$0.75-25.00%MissN/A20 up, 0 downAug 7, 2024
    Mar 31, 2024-$1.50-$1.35-$1.35 - -$0.75-11.11%MissN/A20 up, 0 downMay 9, 2024
    Dec 31, 2023-$0.05-$0.08-$0.09 - -$0.08+37.50%BeatN/A20 up, 0 downMar 11, 2024
    Sep 30, 2023-$0.08N/AN/AN/AN/AN/AN/AN/ANov 9, 2023
    Jun 30, 2023-$1.35N/AN/AN/AN/AN/AN/AN/AAug 10, 2023
    Mar 31, 2023-$6.62N/AN/AN/AN/AN/AN/AN/AMay 10, 2023
    Dec 31, 2022-$0.85N/AN/AN/AN/AN/AN/AN/AMar 29, 2023
    Jun 30, 2022-$0.06N/AN/AN/AN/AN/AN/AN/ASep 22, 2022
    Last 16 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$6.68, after -$8.48 the year before. It was -$0.91 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$6.68N/A
    Dec 31, 2024-$8.48N/A
    Dec 31, 2023-$8.10N/A
    Dec 31, 2022-$0.91N/A

    Frequently Asked Questions About CVKD

    When is Cadrenal Therapeutics, Inc. Common Stock's next earnings date?

    Cadrenal Therapeutics, Inc. Common Stock's next earnings report is expected for Mar 29, 2027.

    Did CVKD beat earnings estimates last quarter?

    Yes. Cadrenal Therapeutics, Inc. Common Stock reported EPS of -$1.14 for the quarter ended Jun 30, 2026, above the -$1.16 estimate, a 1.72% surprise.

    What EPS do analysts expect from CVKD next quarter?

    The consensus EPS estimate for Cadrenal Therapeutics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.88 from 5 analysts.

    How often does CVKD beat earnings estimates?

    Cadrenal Therapeutics, Inc. Common Stock beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -5.60%.